Evidence map›Paper›PMID 40797342›Full record

ReviewBiomarker research2025

Therapeutic landscape of ovarian cancer: recent advances and emerging therapies.

Ling Wang, Qun Zhang, Xue Wang, Zixuan Dong, Shanshan Liu, Qi Wang, Zhiqiang Zhang, Junji Xing

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomarker research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Autophagy in Ovarian Cancer, an Opportunity or an Additional Threat?International journal of molecular sciences · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ling WangDepartment of Gynecology and Obstetrics, The Second Norman Bethune Hospital of Jilin University, 218 Ziqiang Street, Changchun, Jilin, 130041, China.
Qun ZhangDepartment of Gynecology and Obstetrics, The Second Norman Bethune Hospital of Jilin University, 218 Ziqiang Street, Changchun, Jilin, 130041, China.
Xue WangDepartment of Gynecology and Obstetrics, The Second Norman Bethune Hospital of Jilin University, 218 Ziqiang Street, Changchun, Jilin, 130041, China.
Zixuan DongDepartment of Gynecology and Obstetrics, The Second Norman Bethune Hospital of Jilin University, 218 Ziqiang Street, Changchun, Jilin, 130041, China.
Shanshan LiuDepartment of Gynecology and Obstetrics, The Second Norman Bethune Hospital of Jilin University, 218 Ziqiang Street, Changchun, Jilin, 130041, China.
Qi Wang *Department of Gynecologic Oncology, First Ward, Jilin Provincial Cancer Hospital, 1018 Huguang Street, Changchun, Jilin, 130022, China. 2445703150@qq.com.
Zhiqiang Zhang *Immunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Academic Institute, Houston Methodist, Houston, TX, 77030, USA. zzhang@houstonmethodist.org.
Junji Xing *Immunobiology and Transplant Science Center, Department of Surgery, Houston Methodist Academic Institute, Houston Methodist, Houston, TX, 77030, USA. jxing@houstonmethodist.org.

Funding

Studies of a new checkpoint regulator in the control of intestinal inflammationR01AI155488 · NIAID · METHODIST HOSPITAL RESEARCH INSTITUTE · PI ZHANG, ZHIQIANG · 2021 to 2025
$2.0M
American Heart Association 20CDA35260116Natural Science Foundation of Jilin Province YDZJ202201ZYTS111Natural Science Foundation of Jilin Province YDZJ202301ZYTS052NIAID NIH HHS R01 AI155488NIH HHS R01AI155488
6 · The paper itself

Abstract

Ovarian cancer ranks as the seventh most common malignancy and the eighth leading cause of cancer-related death in women worldwide. Most patients are diagnosed at an advanced stage, resulting in poor survival outcomes. The standard treatment is primary debulking surgery (PDS) with platinum-based chemotherapy, however interval debulking surgery (IDS) following neoadjuvant chemotherapy (NACT) is an alternative for select cases. In this review, we summarize recent advancements in the therapeutic landscape of ovarian cancer, focusing on targeted therapies, immunotherapy, and novel drug delivery systems. Poly (ADP-ribose) polymerase (PARP) inhibitors have markedly improved progression-free survival in BRCA-mutated and homologous recombination deficiency (HRD)-positive patients. Antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), chimeric antigen receptor T (CAR-T) cell therapy, and tumor vaccines are emerging strategies, but they face challenges due to treatment resistance and tumor microenvironment suppression. Future research should focus on combination therapies, ADCs optimization, and immunotherapy refinement, while also integrating nanotechnology and 3D organoid models to enhance treatment precision to improve survival outcomes and quality of life for ovarian cancer patients.

Indexed as

Antibody-drug conjugates (ADCs)Chimeric antigen receptor T (CAR-T) cell therapyImmune checkpoint inhibitorsImmunotherapyOvarian cancerPARP inhibitorsTumor vaccines

Identifiers

PMID40797342
PMCPMC12344919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.